Erythema dyschromicum perstans (ashy dermatosis) during the treatment with infliximab in a child with Crohn disease

Lange, Magdalena; Lakomy, Joanna

doi:10.5114/dr.2014.41068

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenesis of erythema dyschromicum perstans is still unknown. Several predisposing factors have been cited, including hypothyroidism, HLA-DR4 allele carriers [7], infections such as whipworm infestation [8], human immunodeficiency virus [9], chronic hepatitis C infection (HCV) [10], toxic substance exposure such as ingestion of ammonium nitrate [11], contrast media [12], and medication such as ethambutol [13], chlorothalonil [14], and omeprazole [15].…”

Section: Discussionmentioning

confidence: 99%

Erythema Dyschromicum Perstans After Adalimumab Treatment

Alsisi¹,

Alsisi²,

Alhowaish³

et al. 2022

Cureus

View full text Add to dashboard Cite

Tumor necrosis factor (TNF) is a cytokine that regulates immunity by binding to the cytokine receptor (TNFR), which has a role in treating inflammatory, neoplastic, and autoimmune diseases. Medications, including etanercept, infliximab, and adalimumab, are examples of TNF-alpha blockers. Adalimumab is a fully human immunoglobulin monoclonal antibody approved for use in the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease, and hidradenitis suppurativa according to the American College of Rheumatology. However, there are few reports of cases where its administration was associated with skin reactions. In the present paper, we report a case of a psoriatic male patient who developed a cutaneous reaction of the face following treatment with adalimumab.

show abstract